看多
$RXMD Massively Underpriced and Oversold at Key Support
$RXMD is in a clear bullish technical posture: at key support with multiple touches over two years and an RSI print under the "30" bull signal level. In other words, it's oversold and triggering key support in a very large time-frame bull trend.
• Telehealth regulations have been dropped to allow it to brace our healthcare system against exponential COVID-19 case growth.
• RXMD is currently priced at 0.5x trailing sales, which is extremely cheap, even for a pharmacy play.
• This is especially true given that it just posted 56% top-line growth and is moving toward the likely launch of a telemedicine platform.
• RXMD is moving toward a NASDAQ or NYSE uplisting.
• Telehealth regulations have been dropped to allow it to brace our healthcare system against exponential COVID-19 case growth.
• RXMD is currently priced at 0.5x trailing sales, which is extremely cheap, even for a pharmacy play.
• This is especially true given that it just posted 56% top-line growth and is moving toward the likely launch of a telemedicine platform.
• RXMD is moving toward a NASDAQ or NYSE uplisting.
免責聲明
這些資訊和出版物並不意味著也不構成TradingView提供或認可的金融、投資、交易或其他類型的意見或建議。請在使用條款閱讀更多資訊。